Investigation of the recurrence patterns of gastric cancer following a curative resection

Deng, Jingyu; Liang, Han; Wang, Dianchang; Sun, Dan; Pan, Yi; Liu, Yong

doi:10.1007/s00595-009-4251-y

Cited by 82 publications

(65 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2005, 300,000 mortalities and 400,000 new cases of gastric cancer were reported in China (2). Metastasis from gastric cancer typically occurs in the abdominal cavity, peritoneum, lymph nodes and liver (3). Metastasis limited to the brain is rare and prognosis in such cases is poor (4,5).…”

Section: Introductionmentioning

confidence: 99%

A case report of gastric cancer with brain metastasis: Rare peripheral nervous system symptoms

et al. 2016

View full text Add to dashboard Cite

Abstract. Gastric cancer with brain metastasis is rare. The present study reports a case of gastric cancer with isolated brain metastasis 1 year after gastrectomy. To the best of our knowledge, there have been no prior reports of solitary brain metastasis from gastric cancer with peripheral nervous system symptoms. A distal gastrectomy was performed on a 60-year-old male patient with gastric cancer in November 2012. Postoperative pathological analysis revealed a moderately differentiated adenocarcinoma with tumor invasion into the serosa and metastasis to one dissected lymph node. No abnormalities were found at follow-up examination. However, a tumor representing metastasis to the brain was recognized by a cranial enhanced magnetic resonance imaging examination 1 year after gastrectomy, which was performed when the patient exhibited numbness and thigmesthesia. The patient was administered 30 Gy of stereotactic radiotherapy, delivered in 5 fractions. The patient succumbed to disease 10 months subsequent to undergoing radiotherapy. This case report suggests that gastric cancer may re-present as brain metastasis with peripheral nervous system symptoms.

show abstract

Section: Introductionmentioning

confidence: 99%

A case report of gastric cancer with brain metastasis: Rare peripheral nervous system symptoms

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Three-year disease free survival was used for the primary endpoint of this study because most relapses occur within 3 years after surgery [18]. Secondary end points included 3-year OS and toxicity.…”

Section: Discussionmentioning

confidence: 99%

“…Three-year DFS was used for the primary endpoint of this study because most relapses occur within 3 years after surgery and is strongly correlated with 5-year OS [18]. A meta-analysis of individual patient data collected in randomized clinical trials found that DFS is an acceptable surrogate for OS in trials of cytotoxic agents for gastric cancer in the adjuvant setting and has been widely used in many trials, including the CLASSIC and SAMIT trial [20].…”

Section: Discussionmentioning

confidence: 99%

Adjuvant Capecitabine and Oxaliplatin vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 Gastrectomy

Sun¹,

He²,

Lin³

et al. 2017

J Carcinog Mutagen

View full text Add to dashboard Cite

Objective: This retrospective study was carried out to compare the safety and efficacy of adjuvant capecitabine/ oxaliplatin (XELOX) versus capecitabine/paclitaxel (XP) in gastric cancer patients after D2 gastrectomy. Methods:The hospital records of the First Affiliated Hospital of Nanjing Medical University from 2008-2012 were searched to identify patients treated with adjuvant XELOX or XP after D2 gastrectomy and their clinicopathological data were retrieved. Disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier method with log-rank test.Results: A total of 144 stage I-III patients who received adjuvant XELOX (n=89) or XP (n=55) after D2 gastrectomy were identified. The median follow-up time was 47.0 (25.0-80.0) months. The 3-year DFS and OS rate was 67.0% versus 50.8% (p=0.047) and 74.8% versus 63.5% (p=0.184) in the XELOX and XP group respectively. XELOX significantly reduced the risk of relapse at three years (HR 0.60, 95% CI 0.36-0.99) but did not reduced the risk of death at the third year (HR 0.66,) compared with that treated with XP. Conclusions:These results indicate that adjuvant XELOX after D2 gastrectomy has a clinical advantage over XP; however, prospective studies are needed to verify this finding.

show abstract

“…Recurrences usually present in the abdominal cavity, peritoneum, lymph nodes, and liver. 3,4 Isolated recurrence limited to bone and bone marrow is rare, and prognosis in such cases is poor. 5 We report a rare case of skeletal metastasis in a case of poorly differentiated gastric cancer after adjuvant chemo and a disease free period of seven months in 1 and half -year follow-up.…”

Section: Introductionmentioning

confidence: 99%

A Case Report of Bone Metastasis from Gastric Cancer

Pattanayak¹

2017

MOJS

View full text Add to dashboard Cite

Background: Bone metastasis is an uncommon event in metastatic gastric cancer patients and rarely detected as isolated lesions. A case featuring unusual skeletal metastasis of gastric cancer is presented.Case report: A 60year old man presented with metastasis in the lumber vertebra one and half years after surgery (distal radical gastrectomy for gastric carcinoma). The histopathology of primary tumor was poorly differentiated adenocarcinoma. Patient had received five cycles of adjuvant chemotherapy (Paclitaxel+ Carboplatin) before he presented with lumber vertebra metastasis with a seven month disease free period. Discussion:The metastatic path of gastric cancer cells is generally hematogenous. Higher incidence of bone metastasis occurs in the axial skeleton. Prognosis of patients exhibiting bone metastases from Gastric cancer is worse compared with other solid tumours. Conclusion:Skeletal metastasis is an uncommon event in advanced metastatic Gastric cancer though not rare. The clinician must screen the patient for skeletal lesions right from the time of initial diagnosis.

show abstract

Investigation of the recurrence patterns of gastric cancer following a curative resection

Abstract: Locoregional recurrence, peritoneal dissemination, and distant metastasis were the most common recurrence patterns of gastric cancer following a curative resection. Each recurrence pattern is associated with specific clinicopathological factors.

Cited by 82 publications

References 29 publications

A case report of gastric cancer with brain metastasis: Rare peripheral nervous system symptoms

A case report of gastric cancer with brain metastasis: Rare peripheral nervous system symptoms

Adjuvant Capecitabine and Oxaliplatin vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 Gastrectomy

A Case Report of Bone Metastasis from Gastric Cancer

Contact Info

Product

Resources

About